γδTDEs: An Efficient Delivery System for miR-138 with Anti-tumoral and Immunostimulatory Roles on Oral Squamous Cell Carcinoma.
drug delivery system
extracellular vesicle
miRNA
oral squamous cell carcinoma
γδ T cell
Journal
Molecular therapy. Nucleic acids
ISSN: 2162-2531
Titre abrégé: Mol Ther Nucleic Acids
Pays: United States
ID NLM: 101581621
Informations de publication
Date de publication:
01 Mar 2019
01 Mar 2019
Historique:
received:
28
07
2018
revised:
11
11
2018
accepted:
16
11
2018
pubmed:
30
12
2018
medline:
30
12
2018
entrez:
30
12
2018
Statut:
ppublish
Résumé
In this study, we sought to investigate the potential application of γδ T cell-derived extracellular vesicles (γδTDEs) as drug delivery system (DDS) for miR-138 in the treatment of oral squamous cell carcinoma (OSCC). Our data showed that overexpression of miR-138 in γδ T cells obtained miR-138-rich γδTDEs accompanying increased expansion and cytotoxicity of γδ T cells. γδTDEs inherited the cytotoxic profile of γδ T cells and could efficiently deliver miR-138 to OSCC cells, resulting in synergetic inhibition on OSCC both in vitro and in vivo. The pre-immunization by miR-138-rich γδTDEs inhibited the growth of OSCC tumors in immunocompetent C3H mice, but not in nude mice, suggesting an immunomodulatory role by miR-13-rich γδTDEs. γδTDEs and miR-138 additively increased the proliferation, interferon-γ (IFN-γ) production, and cytotoxicity of CD8
Identifiants
pubmed: 30594069
pii: S2162-2531(18)30303-2
doi: 10.1016/j.omtn.2018.11.009
pmc: PMC6307324
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101-113Informations de copyright
Copyright © 2018. Published by Elsevier Inc.
Références
J Immunol. 2002 Apr 1;168(7):3235-41
pubmed: 11907077
Arthritis Rheum. 2003 Jan;48(1):174-85
pubmed: 12528117
Cell. 2005 Jan 14;120(1):15-20
pubmed: 15652477
J Transl Med. 2005 Mar 02;3(1):10
pubmed: 15740633
Science. 2005 Jul 8;309(5732):264-8
pubmed: 15933162
Clin Cancer Res. 2008 May 1;14(9):2588-92
pubmed: 18451220
Oral Oncol. 2009 Apr-May;45(4-5):309-16
pubmed: 18804401
Cytotherapy. 2008;10(8):842-56
pubmed: 19016372
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Comp Funct Genomics. 2009;:837514
pubmed: 19753298
J Proteomics. 2010 Sep 10;73(10):1907-20
pubmed: 20601276
Semin Cancer Biol. 2011 Apr;21(2):139-46
pubmed: 21251983
Cancer Immunol Immunother. 2012 Mar;61(3):385-96
pubmed: 21928126
J Vis Exp. 2011 Sep 09;(55):null
pubmed: 21931292
Cancer Lett. 2012 Feb 1;315(1):28-37
pubmed: 22055459
Curr Gene Ther. 2012 Aug;12(4):262-74
pubmed: 22856601
J Immunol. 2012 Sep 15;189(6):2833-42
pubmed: 22904309
Curr Opin Oncol. 2013 Jan;25(1):66-75
pubmed: 23165142
Nat Rev Immunol. 2013 Feb;13(2):88-100
pubmed: 23348415
Cancer Lett. 2013 Jul 10;335(1):201-4
pubmed: 23419525
Int Rev Cell Mol Biol. 2013;303:357-85
pubmed: 23445815
J Clin Invest. 2013 Apr;123(4):1542-55
pubmed: 23454749
Oncoimmunology. 2013 Jan 1;2(1):e22337
pubmed: 23482694
Int J Oncol. 2014 Nov;45(5):1847-56
pubmed: 25189159
Oncotarget. 2015 Jan 1;6(1):71-84
pubmed: 25428916
J Oral Pathol Med. 2015 Nov;44(10):792-800
pubmed: 25482863
Front Immunol. 2014 Nov 24;5:607
pubmed: 25505472
Cancer Res. 2015 Mar 1;75(5):798-802
pubmed: 25660949
Oncoimmunology. 2015 Jan 22;4(3):e992749
pubmed: 25949914
Immunol Lett. 2015 Jul;166(1):55-62
pubmed: 26045321
Nat Rev Immunol. 2015 Nov;15(11):683-91
pubmed: 26449179
Adv Drug Deliv Rev. 2015 Dec 1;95:50-5
pubmed: 26482189
Oncotarget. 2015 Dec 29;6(42):44179-90
pubmed: 26496034
Neuro Oncol. 2016 May;18(5):639-48
pubmed: 26658052
Adv Drug Deliv Rev. 2016 Nov 15;106(Pt A):148-156
pubmed: 26928656
Cancer Res. 2016 Apr 1;76(7):1770-80
pubmed: 26992424
J Clin Invest. 2016 Apr 1;126(4):1224-32
pubmed: 27035813
Oncoimmunology. 2015 Aug 12;5(4):e1071008
pubmed: 27141373
Ann Oncol. 2016 Sep;27(9):1675-85
pubmed: 27380958
Cancer Res. 2016 Oct 1;76(19):5832-5844
pubmed: 27569215
Front Cell Dev Biol. 2016 Aug 17;4:84
pubmed: 27583248
Int J Cancer. 2017 Aug 1;141(3):428-436
pubmed: 28247946
Trends Biotechnol. 2017 Jul;35(7):665-676
pubmed: 28365132
Tumour Biol. 2017 Apr;39(4):1010428317697575
pubmed: 28378633
Nature. 2017 Jun 22;546(7659):498-503
pubmed: 28607485
Theranostics. 2017 Jul 7;7(10):2732-2745
pubmed: 28819459
J Control Release. 2017 Nov 28;266:8-16
pubmed: 28916446
Oncoimmunology. 2017 Jul 19;6(8):e1261243
pubmed: 28919985
Nanomedicine. 2018 Jan;14(1):195-204
pubmed: 28982587
Philos Trans R Soc Lond B Biol Sci. 2018 Jan 5;373(1737):
pubmed: 29158310
Front Immunol. 2017 Oct 27;8:1401
pubmed: 29163482
Mol Pharm. 2018 Sep 4;15(9):3625-3633
pubmed: 29771531
Nat Commun. 2018 Jun 15;9(1):2359
pubmed: 29907766
Mol Ther. 2018 Sep 5;26(9):2119-2130
pubmed: 30005869
Nat Med. 1998 May;4(5):594-600
pubmed: 9585234